Objective. To analyse the validity of patient reports on adverse drug reactions (ADRs) compared with the reports given by the treating physician.
Introduction
Randomized clinical Phase III trials are powered to detect differences in efficacy between treatment arms.
They are usually underpowered for the evaluation of the safety profile of drugs, especially for the detection of rare serious adverse events (AEs). Therefore, with the advent of more and more new drugs, pharmacovigilance after licensing has become crucial.
Systems for spontaneous reporting of adverse drug reactions (ADRs) to the health authorities are important tools for the detection of possible safety signals in licensed drugs. However, they heavily underestimate the true incidence of possible ADRs, even serious ADRs [1] . Many physicians may refrain from reporting ADRs due to the fear of bureaucratic burden. In a recent report, the World Health Organization urged all health professionals worldwide to increase their efforts in the reporting of ADRs [2] .
During the past decade, it has been repeatedly discussed whether the completeness of reporting could be enhanced by integration of patient reports of ADRs and to which extent these reports can complete physician reports. Direct patient reporting of suspected ADRs to spontaneous reporting systems may raise public awareness of potentially harmful effects of drugs and lead to more comprehensive capture of the potential risks of drugs [3, 4] .
Therefore, since October 2005, the Yellow Card Scheme in the UK has been open for direct patient reports [5] . Several countries, among them the United States, Canada, Australia, Denmark, The Netherlands and Sweden, have incorporated patient reports into their pharmacovigilance systems [6] . So far, there is little published evidence on the validity of these reports [7] .
There are a number of questions concerning the validity of patient-reported ADRs:
(i) How valid is the information given by the patient against the background of physician-reported ADRs?
(ii) How large is the overlap of physician-and patientreported ADRs? Can patient reports replace the physician reports?
(iii) Are there any differences among the individual ADRs regarding agreement between physicians and patients?
These questions can be answered only within systems where physicians and patients routinely report ADRs at identical time points. The German biologics register rheumatoid arthritis observation of biologic therapy (RABBIT) [8] investigates the long-term safety of all biologic agents licensed for the treatment of RA. In addition to regular physician reports, data on ADRs are gathered from patients at all visits. In the following analysis, we used the physician reports as the gold standard and analyse the agreement of patient reports with these physician-derived reports.
Methods

Source of data
RABBIT is a long-term observational cohort study investigating the long-term safety in patients with RA treated with one of the new biological agents or a conventional disease-modifying anti-rheumatic drug (DMARD). The study received ethical approval in 2001. Further details of the study design were published previously [9, 10] . Patients enrolled in RABBIT between May 2001 and September 2006, who had at least one follow-up visit, were included in this analysis.
Coding of AEs
Each AE was coded centrally in the study centre as a specific unambiguous term (preferred term) using the Medical Dictionary for Regulatory Activities [MedDRA, version 9.0(11)] by a trained physician (A.S.) or an advanced medical student (L.G.) under supervision. Patient-reported ADRs were coded without knowing the concomitant physician report.
MedDRA is a clinically validated, internationally used, multi-hierarchical dictionary. It was developed by the International Conference on Harmonisation (ICH) and is used by international regulatory authorities and the biopharmaceutical industry. Since 2003, it is mandatory that all reportings of (drug-related) AEs to the European Medicines Agency be MedDRA coded. The dictionary is divided into 26 system organ classes (such as gastrointestinal disorders), then subdivided into 338 high-level group terms (HLGTs; e.g. gastrointestinal signs and symptoms) containing 1667 high-level terms (HLTs; e.g. dyspeptic signs and symptoms). These HLTs aggregate 11 107 preferred terms (PTs; e.g. dyspepsia).
Methods of comparing ADR reports
At all time points of follow-up, physicians documented any new sign or symptom, any hospitalization and any worsening of a comorbid condition as AE, irrespective of a causal relationship with the prescribed drugs. In addition, they assessed the severity and seriousness of the event following the recommendations of the ICH guideline [12] and the probability of causality to the drug taken. At the same time points, patients were asked in an open-ended question whether they had experienced any potential side effects of the prescribed anti-rheumatic drugs since last follow-up. Patients graded the side effect as mild, moderate or severe, and reported whether they had to see a doctor or were on sick leave due to the ADR. Therefore, the patients were asked for events where they saw at least a possible relationship with a drug, whereas physicians were asked for AEs in general. In order to be able to compare both, we included only those physician reports in the analysis that had a definite, probable, possible or unknown relation with a drug, thus fulfilling the definition of an ADR. Reports about events rated as having an unlikely or no causality to the drug were excluded. They compromised 22.9% of a total of 8110 reports. Only data of patients where both physician and patient questionnaires were available for baseline and at least one follow-up visit were included in the analysis.
To report the general spectrum and overall frequency of reported ADRs, we used the most aggregated level of MedDRA, the HLGTs. For this analysis we counted all ADRs reported at any time point within the whole follow-up period (results are shown in Table 1 ). To analyse the agreement between patient-and physician-reported ADRs, we compared only events reported for the individual patient at the same time point (cross-sectional approach). HLGTs that include investigations rather than diagnoses were excluded from the analysis [e.g. bone and www.rheumatology.oxfordjournals.org
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Validity of patient reports on adverse drug reactions joint therapeutic procedures (n = 72) and hepatobiliary investigations (n = 290)].
Furthermore, some HLGTs that are closely related to each other were summarized as one group. As a result, the group gastrointestinal disorders consists of the HLGTs gastrointestinal signs and symptoms, gastrointestinal motility and defaecation conditions and gastrointestinal inflammatory conditions. The group infections consists of the HLGTs infections-pathogen class unspecified, viral infectious disorders, bacterial infectious disorders and fungal infectious disorders and the group skin disorders consists of the HLGTs epidermal and dermal conditions and skin appendage conditions. Since physicians and patients use different languages (medical terminology vs lay description) that may lead to different PTs, we also applied a broader definition approach in which we compared selected ADRs even on the plain text level. For each physician-reported ADR, all patient-reported ADRs at the same time were considered. The first author (L.G.) then rated whether there was an agreement between patient and physician or at least an association (meaning that patients may have described the same event in different words, e.g. pneumonia with dyspnoea and cough). The exact definitions used for the selected terms are shown in Table 2 .
Statistical analysis
Descriptive statistics were used to examine the study population demographics. To compare patients with and without any reported ADRs, chi-squared tests and MannWhitney U-tests were applied, and for age and DAS-28, ttests were applied. P < 0.05 was considered to be statistically significant. Data analysis was performed with SPSS 15.0.1 (SPSS Inc.; Chicago, IL, USA). As a measure of agreement k-values were calculated.
Results
Overall ADR reports
Out of 4246 patients who were observed for a median of 1.8 years, 2744 (64.6%) had at least one ADR reported by the physician or the patient. The mean number of reported ADRs (either by physician or by patient) was 1.9 per patient (S.D. 1.3). Those patients without any ADR had a shorter median observation period (1.1 years). However, this shorter observation period has probably only a minor influence on the occurrence rate, since 88% of all ADRs were reported within the first 12 months (76% within the first 6 months). Patients with and without ADRs did not differ in age or disease activity except for morning The patient identified his blood pressure as too high (hypertension, increased blood pressure, high blood pressure, etc.).
The patient understood that the adverse event has something to do with his heart or vessels (heart).
Anaphylactic shock
Anaphylactic reaction, anaphylactic shock and anaphylactoid reaction
The patient used the word anaphylactic shock or described a heavy allergic reaction. 
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Validity of patient reports on adverse drug reactions stiffness, which was more present in patients with ADRs. Those patients with ADRs were more often female, had a higher educational level and a poorer self-reported health condition. There were no differences between the two groups concerning treatment with glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs). However, patients that reported ADRs were less often treated with biologics (Table 3) .
Comparing the overall frequency and distribution of reported ADRs
In general, physicians reported a considerably smaller number of ADRs than patients. A total of 6256 events were reported by physicians and 9671 by patients, resulting in 782 vs 1210 events/1000 patient-years (PYs). Gastrointestinal disorders, infections and skin disorders were the most frequently reported ADRs by physicians; patients reported fewer infections and more general system disorders (Table 1) .
Infections and administration site reactions were significantly more frequently reported by physicians than by patients. Relatively high agreement in frequencies of reports were found for the HLGTs vascular hypertensive disorders (19 vs 25/1000 PYs), oral soft tissue disorders (14 vs 19/ 1000 PYs) and cardiac arrhythmias (6 vs 8/1000 PYs). The number of reports of rare events like ocular and tissue disorders as well as anxiety symptoms did not differ significantly between patients and physicians. All other ADRs were significantly more often reported by the patients, especially general system disorders (including fatigue or malaise), changes in weight, neurological disorders such as dizziness and headaches and vision disorders.
However, similar overall frequencies of reported ADRs in this table do not necessarily mean agreement between physician and patient reports in individual patients and at the same time point.
Individual agreement of patients and physicians on HLGT level
For the 10 most frequently reported HLGTs, we investigated the agreement in individual patients. Figure 1 shows the percentage of patients in which both the physician and the patient mentioned an event of the same HLGT at the same time. In addition, it shows how often a HLGT was reported either by the physician or by the patient only. Agreement never exceeded 35% in any of the HLGTs. The highest agreement rates were found in easily observable and verifiable events, like oral soft tissue conditions (mostly stomatitis) and skin disorders. Half of all administration site reactions and 54% of all infections were reported by the physician only, whereas 64% of all general disorders and 59% of all neurological disorders or headaches were reported by patients only.
One of the reasons for the low level of agreement is a different terminology used by patients compared with physicians. To investigate the principal agreement (reporting of the same event but describing it with different words), we defined broader groups of diagnoses ('Methods' section and Table 2 ). Based on these definitions, the level of agreement between physician and patient reports increased considerably. For administration site reactions, for example, the agreement rate increased from 29.2 (comparison of strictly MedDRA coded PT terms) to 39.8% when the broader definition was applied, taking the different terminology of physicians and patients into account. The level of agreement could be increased further to 56.2% when diagnoses or symptoms that were at least associated were considered as reports of the same ADR (see Table 2 for details). However, the increase in agreement was not seen for all diagnoses. Although pneumonia is a well-defined condition that can be expected to be reported by patients, the agreement of reports was surprisingly low. Even with the broadest definition, the low agreement rate of 26.4% could only be increased to an agreement rate of 37.7% when similar conditions such as cough or fever were considered as symptoms of the same event.
Agreement of patient and physician in rare events
We further investigated how well rare events could be detected via patient reports. Anaphylactic shock was reported in correct or similar wording by 50% of the 12 patients in whom the physician had reported this event. In contrast, very low agreement existed for the reporting of neoplasms. Only 20% of patients with neoplasms (n = 19) reported the diagnosis or something associated. Similar rates of non-reporting were found for sepsis (78% disagreement). Even tuberculosis was only reported by five out of nine patients who had experienced this event (Table 4 ).
Discussion
In current clinical routine, the physician's report is the main source for recording ADRs and for registering new or severe ADRs. In recent years, it has been discussed controversially whether to include patient-reported ADRs in pharmacovigilance databases and how valid these reports are.
Reasons to open the reporting systems for patients are 2-fold. First, patients tend to provide a more detailed description of side effects, including information on the impact on the quality of life [13] ; and secondly, patients may contribute to earlier detection of known and unknown ADRs [14] . This is particularly important for serious effects that require prompt action from the Medicines and Healthcare Products Regulatory Agency. Therefore, the International Society of Drug Bulletins (ISDB) recommends the development of systems for direct patient reporting [14] .
Aside from spontaneous reporting systems, patientreported ADRs can also be implemented in the framework of randomized clinical trials and observational cohort studies. There have been attempts in the past to include patient reporting and nurse reporting of ADRs in cancer treatment trials [15, 16] .
Van den Bemt et al. [17] compared ADRs reported by patients, nurses and doctors in 620 hospitalized patients in The Netherlands in 1999. Patients on four wards were interviewed daily by a pharmacist within a period of 2 months. Their reports were compared with the reports made by separately instructed physicians. The authors found that the patients reported six times more unexpected (55 vs 9) and 4.5 times more serious ADRs (27 vs 6) compared with the physicians. We found that the patients reported 1.6 times more ADRs than the physicians. Patients tended to report more subjective symptoms such as nausea, general symptoms and skin disorders, whereas physicians reported considerably more infections and administration site reactions.
This result is in agreement with a study from Basch et al. [16] , who compared standardized ADR reports from physicians and patients in lung cancer patients receiving chemotherapy. The physicians' reports predicted clinical events better, whereas the patients' reports were more 
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Validity of patient reports on adverse drug reactions reflective of the patients' daily health status and quality of life. In a study with 37 men with prostate cancer, a standardized instrument for patient-reported ADRs and the study's adverse events log were compared [18] . Taking the patient as the gold standard, the overall physician sensitivity was 47% and the specificity was 68%.
Basch et al. [19] analysed the agreement in reported symptoms between 400 outpatients with genitourinary or lung cancer and their clinicians (physicians and nurses). They used a questionnaire with 11 common symptoms that should be graded according to their severity. Generally, the agreement was high for symptoms like vomiting (96%), nausea (90%) or diarrhoea (85%). The agreement for fatigue (55%) or dyspnoea (52%) was smaller but still clearly higher than in our study.
We found good agreement between the individual patient and the physician for easily observable, objective symptoms (e.g. 76% for alopecia) and low agreement for more subjective ones (e.g. 13% agreement for general system disorders such as fatigue and malaise). In 2008, de Langen et al. [13] analysed the experiences of the first 3 years of patient reporting of ADRs to the spontaneous reporting system in The Netherlands. Similar to our study, they found that patients tended to report ADRs that influence the quality of life, such as fatigue and decreased libido, with higher frequency than physicians.
Often these subjective ADRs have a greater impact on the patients' well-being. For example, fatigue can heavily influence the patients' everyday tasks, attitudes and leisure time, and has great importance in quality of life [20] .
Our study has strengths and limitations. Its strength is that it analyses agreement between patients and physicians for individual ADRs and for individual follow-up time points. All reported ADRs were encoded with the same coding system (MedDRA). We were therefore able to analyse for each physician-reported ADR whether the patient reported the same or a similar ADR. Furthermore, our data are generalizable to daily rheumatologic care, since the register includes unselected patients of outpatient clinics and rheumatological practices at the start of a new therapy with biologic or synthetic DMARDs. They represent the spectrum of all patients seen in daily care. Due to their differences in age, comorbidities, disease activity and functional capacity, only 21-33% of the patients included in our register would have been eligible for the major clinical trials [21] .
Our findings suggest that, even though there was considerable overlap between physician and patient reports, there are some ADRs where patients tend not to see the connection between their symptom and drug intake. For example, only one-third of physician-reported infections were reported by the patient as well.
The limitations of our study are the following: by using the coding system MedDRA, small differences in describing an AE could lead to a different PT and may therefore lead to another HLGT. For example, if the patient described a symptom of a disease he or she experienced (such as cough) while the physician named the disease (such as upper respiratory tract infection), coding with MedDRA would lead to different HLGTs. In this example it would lead to 'respiratory disorders NEC' in the patient's case and to 'infections-pathogen unspecified' in the physician's case. To overcome this problem, we also compared physician-reported ADRs with the patient-reported ADRs on the plain text level. Using this broader definition, which takes into account differing lay descriptions of medical conditions, increased the level of agreement from one-third to more than one-half of the cases.
This raises the question of the best method for collecting patient-reported ADRs. We used open-ended questions and coded the reported events. A study by Bent et al. [22] showed that the number of reported events could be increased substantially when checklists are applied. However, they might have very low specificity for detecting true side effects.
Summing up, our article adds to the understanding of the validity of patient-reported ADRs. We showed that agreement between patients' and physicians' reports is highly dependent on the nature of the reported ADR. The low agreement in subjective ADRs may in part be due to underreporting by physicians.
Conclusion
Subjective ADRs without observable correlates (which can have a tremendous impact on the quality of life) are reported considerably more often by patients than by physicians. On the other hand, our results show that it is often difficult for patients to see a potential relationship between a certain health problem and drug intake. Given the discrepancies between physician and patient reports, patient reports of ADRs will never be able to replace physician reports. Nevertheless, patient reports, in standardized or open-ended format, should be seen as an important completion of the drug safety assessment and should be included in further pharmacovigilance studies.
Rheumatology key messages
. Reliable pharmacovigilance data cannot be gained without physician-derived reports on ADRs. . Patient reports are important to capture the complete spectrum of ADRs. . Pharmacovigilance studies should use both patient and physician reports whenever possible.
